OpenAI acquires Orchestra Bio to bring AI agents into drug development
OpenAI completed an acquisition of Orchestra Bio, a startup that builds AI agents designed to assist pharmaceutical teams in managing development programs. The Orchestra Bio team and technology will be integrated into OpenAI's Rosalind life sciences unit. The deal reflects OpenAI's strategy to expand AI applications into regulated industries and specialized domains like drug development.
Key points
- OpenAI acquired Orchestra Bio, a pharma AI software startup
- Orchestra Bio builds AI agents for pharmaceutical development program management
- Integration into OpenAI's Rosalind life sciences division
Summary and key points written by AI from the headline and a short excerpt, so they can be incomplete or wrong. SiliconANGLE did the reporting; read the original for the full story.
Read the full story at SiliconANGLE
